The FDA assessed the protection and usefulness of atidarsagene autotemcel depending on information from 37 children who gained atidarsagene autotemcel in two single-arm, open up-label medical trials As well as in an expanded accessibility program.[seven] Young children who received procedure with atidarsagene autotemcel have been in comparison with